Dr Thomas J. Oxley is a Neurologist with an expertise in vascular neurology and neural engineering. He is currently completing a neurointerventional fellowship in New York City, heads a pioneering endovascular bionics research laboratory in the University of Melbourne, Australia, and is the Founding CEO of Synchron, Inc, a startup endovascular neural interface company in Silicon Valley, CA.
Dr Oxley completed both internal medicine and neurology training in 2013 at the Royal Melbourne and Alfred Hospitals, Melbourne, Australia. In 2015, he competed a stroke fellowship at the Royal Melbourne Hospital, and was an investigator in the EXTEND-IA trial that demonstrated the paradigm-shifting efficacy of mechanical thrombectomy in the treatment of stroke, and published in the New England Journal of Medicine. He is currently undertaking a neurointervention fellowship under Dr J Mocco and Dr A Berenstein at Mount Sinai Hospital, Department of Neurosurgery, New York City.
Dr Oxley commenced a PhD in neural engineering in 2012 at the University of Melbourne after securing $1M in seed funding to pursue a blue sky neural interface concept. During his PhD, he raised a total of $4.4 million dollars in funding from US and Australian governments, for the development of a novel stent electrode (stentrode) array. In February 2016, the breakout scientific report of the technology was published in Nature Biotechnology (IF 41). His research laboratory now includes two post-docs, two research engineers, 3 PhD students and 4 honours students. The lab collaborates across 16 departments at the University of Melbourne including medicine, neurology, neurosurgery, engineering, physics and pathology. The research group is working towards a first-in-human clinical trial at the Royal Melbourne Hospital of a pioneering minimally invasive brain-machine interface technology for the thought-control of electronic devices including exoskeletons for patients with paralysis due to spinal cord injury.
Dr Oxley has founded three companies. He is the founding CEO of SmartStent which is pioneering endovascular bionics. SmartStent is commercializing the Stentrode(TM), a minimally invasive brain-machine interface and signal processing technology. SmartStent continues activities in Melbourne, but is now wholly owned by the Silicon Valley startup, Synchron. Synchron recently announced the recruitment of Board Chairman, Martin Dieck. Mr Dieck is a veteran entrepreneur in the neurovascular space with a strong commercialization track record. Dr Oxley has also founded VascuLab: Australia’s first dedicated commercial research and development angiography suite.